losartan has been researched along with Hyperkalemia in 18 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hyperkalemia: Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To retrospectively investigate elevation of serum potassium when spironolactone (25 or 50 mg/day) and furosemide were administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) to patients with chronic heart failure for 12 months and occurrence of hyperkalemia and hypokalemia because of concomitant administration of spironolactone plus an ACE-I or ARB and furosemide." | 9.11 | Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. ( Hirooka, K; Isobe, F; Saito, M; Takada, M; Yasumura, Y, 2005) |
| "Losartan and enalapril may be beneficial in pediatric kidney transplant recipients by decreasing blood pressure and proteinuria, with maintenance of stable graft function, but may be associated with serious adverse events including hyperkalemia and life-threatening acidosis." | 7.80 | Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. ( Baskın, E; Bayrakcı, US; Haberal, M; Moray, G; Sakallı, H, 2014) |
| "Hyperkalemia is a known side effect during treatment with Angiotensin Converting Enzyme Inhibitors (ACEIs)." | 6.71 | Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan). ( Dworkin, L; Yango, A; Zanabli, AR, 2004) |
| "Hyperkalemia is a complications of the use of angiotensin converting enzyme inhibitors, angiotensin receptor antagonists and aldosterone antagonists." | 5.33 | [Severe hyperkalemia associated to the use of losartan and spironolactone: case report]. ( Kauffmann, R; Orozco, R; Venegas, JC, 2005) |
| "To retrospectively investigate elevation of serum potassium when spironolactone (25 or 50 mg/day) and furosemide were administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) to patients with chronic heart failure for 12 months and occurrence of hyperkalemia and hypokalemia because of concomitant administration of spironolactone plus an ACE-I or ARB and furosemide." | 5.11 | Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. ( Hirooka, K; Isobe, F; Saito, M; Takada, M; Yasumura, Y, 2005) |
| "In patients with HF with reduced ejection fraction intolerant to angiotensin-converting enzyme inhibitors and treated with either high- or low-dose losartan, incident hypokalemia had a stronger association with poor outcomes than incident hyperkalemia." | 4.31 | High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL. ( Ferreira, JP; Kiernan, MS; Konstam, M; Rossignol, P; Zannad, F, 2023) |
| "We used myocytes from Wistar, SHR, losartan-treated SHR (Los-SHR), and Angiotensin II (Ang II)-induced cardiac hypertrophy." | 3.80 | Reduced sarcolemmal expression and function of the NBCe1 isoform of the Na⁺-HCO₃⁻ cotransporter in hypertrophied cardiomyocytes of spontaneously hypertensive rats: role of the renin-angiotensin system. ( Aiello, EA; Caldiz, CI; Ciancio, MC; De Giusti, VC; Orlowski, A, 2014) |
| "Losartan and enalapril may be beneficial in pediatric kidney transplant recipients by decreasing blood pressure and proteinuria, with maintenance of stable graft function, but may be associated with serious adverse events including hyperkalemia and life-threatening acidosis." | 3.80 | Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. ( Baskın, E; Bayrakcı, US; Haberal, M; Moray, G; Sakallı, H, 2014) |
| "Arterial hypertension significantly decreased after the introduction of losartan (p = 0." | 3.72 | Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. ( Anaya, F; Campistol, JM; Del Castillo, D; Esforzado, N; Iñigo, P; Navarro, MD; Oppenheimer, F; Saracho, R, 2003) |
| " Daily he took Losartan potassium, an AIIA, due to hypertension and ate preoperatively dried persimmons, a potassium-rich food." | 3.72 | [A case of intraoperative hyperkalemia induced with administration of an angiotensin II receptor antagonist (AIIA) and intake of dried persimmons]. ( Masuda, N; Miyahara, Y; Miyazaki, T; Tamura, T; Tanaka, Y; Uchida, K; Yamashita, S; Yonei, A, 2004) |
| "Hyperkalemia is a known side effect during treatment with Angiotensin Converting Enzyme Inhibitors (ACEIs)." | 2.71 | Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan). ( Dworkin, L; Yango, A; Zanabli, AR, 2004) |
| "Hyperkalemia is a complications of the use of angiotensin converting enzyme inhibitors, angiotensin receptor antagonists and aldosterone antagonists." | 1.33 | [Severe hyperkalemia associated to the use of losartan and spironolactone: case report]. ( Kauffmann, R; Orozco, R; Venegas, JC, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Mårup, FH | 1 |
| Peters, CD | 1 |
| Christensen, JH | 1 |
| Birn, H | 1 |
| Ferreira, JP | 1 |
| Konstam, M | 1 |
| Rossignol, P | 2 |
| Kiernan, MS | 1 |
| Zannad, F | 2 |
| Pitt, B | 1 |
| Bakris, GL | 1 |
| Weir, MR | 1 |
| Freeman, MW | 1 |
| Lainscak, M | 1 |
| Mayo, MR | 1 |
| Garza, D | 1 |
| Zawadzki, R | 1 |
| Berman, L | 1 |
| Bushinsky, DA | 1 |
| Orlowski, A | 1 |
| Ciancio, MC | 1 |
| Caldiz, CI | 1 |
| De Giusti, VC | 1 |
| Aiello, EA | 1 |
| Van Buren, PN | 1 |
| Adams-Huet, B | 1 |
| Nguyen, M | 1 |
| Molina, C | 1 |
| Toto, RD | 1 |
| Sakallı, H | 1 |
| Baskın, E | 1 |
| Bayrakcı, US | 1 |
| Moray, G | 1 |
| Haberal, M | 1 |
| Dobre, D | 1 |
| Gregory, D | 1 |
| Massaro, J | 1 |
| Kiernan, M | 1 |
| Konstam, MA | 1 |
| Woo, KT | 1 |
| Choong, HL | 1 |
| Wong, KS | 1 |
| Tan, HK | 1 |
| Foo, M | 1 |
| Fook-Chong, S | 1 |
| Lee, EJ | 1 |
| Anantharaman, V | 1 |
| Lee, GS | 1 |
| Chan, CM | 1 |
| Fried, LF | 1 |
| Duckworth, W | 1 |
| Zhang, JH | 1 |
| O'Connor, T | 1 |
| Brophy, M | 1 |
| Emanuele, N | 1 |
| Huang, GD | 1 |
| McCullough, PA | 1 |
| Palevsky, PM | 1 |
| Seliger, S | 1 |
| Warren, SR | 1 |
| Peduzzi, P | 1 |
| Giancaspro, G | 1 |
| Suppa, M | 1 |
| Genuini, I | 1 |
| Caselli, S | 1 |
| Fedele, F | 1 |
| Zaki, KS | 1 |
| Majid, U | 1 |
| Islam, N | 1 |
| Iñigo, P | 1 |
| Campistol, JM | 1 |
| Saracho, R | 1 |
| Del Castillo, D | 1 |
| Anaya, F | 1 |
| Esforzado, N | 1 |
| Navarro, MD | 1 |
| Oppenheimer, F | 1 |
| Miyahara, Y | 1 |
| Miyazaki, T | 1 |
| Tanaka, Y | 1 |
| Uchida, K | 1 |
| Tamura, T | 1 |
| Masuda, N | 1 |
| Yamashita, S | 1 |
| Yonei, A | 1 |
| Zanabli, AR | 1 |
| Yango, A | 1 |
| Dworkin, L | 1 |
| Kauffmann, R | 1 |
| Orozco, R | 1 |
| Venegas, JC | 1 |
| Saito, M | 1 |
| Takada, M | 1 |
| Hirooka, K | 1 |
| Isobe, F | 1 |
| Yasumura, Y | 1 |
| Ellis, D | 1 |
| Walser, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and[NCT01371747] | Phase 2 | 324 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Improving Outcomes in Diabetic Nephropathy[NCT00381134] | Phase 2 | 92 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)[NCT00555217] | Phase 3 | 1,448 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to It was stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Least squares mean changes from Baseline to Day 3 were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Day 3
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.26 |
| Stratum 1: 16.8 g/d Patiromer | -0.28 |
| Stratum 1: 25.2 g/d Patiromer | -0.31 |
| Stratum 2: 16.8 g/d Patiromer | -0.65 |
| Stratum 2: 25.2 g/d Patiromer | -0.59 |
| Stratum 2: 33.6 g/d Patiromer | -0.53 |
Least square mean changes from Baseline to Week 4/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 4 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.51 |
| Stratum 1: 25.2 g/d Patiromer | -0.55 |
| Stratum 2: 16.8 g/d Patiromer | -0.87 |
| Stratum 2: 25.2 g/d Patiromer | -0.97 |
| Stratum 2: 33.6 g/d Patiromer | -0.92 |
Least squares mean changes from Baseline to Week 8/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 8 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.47 |
| Stratum 1: 25.2 g/d Patiromer | -0.54 |
| Stratum 2: 16.8 g/d Patiromer | -0.88 |
| Stratum 2: 25.2 g/d Patiromer | -0.95 |
| Stratum 2: 33.6 g/d Patiromer | -0.91 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.54 |
| Stratum 1: 16.8 g/d Patiromer | -0.44 |
| Stratum 1: 25.2 g/d Patiromer | -0.50 |
| Stratum 2: 16.8 g/d Patiromer | -1.00 |
| Stratum 2: 25.2 g/d Patiromer | -0.96 |
| Stratum 2: 33.6 g/d Patiromer | -1.17 |
(NCT01371747)
Timeframe: Week 52 or Last Patiromer Dose (if Occurred before Week 52) to Following up Visit Plus 7 Days
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 0.36 |
| Stratum 1: 16.8 g/d Patiromer | 0.22 |
| Stratum 1: 25.2 g/d Patiromer | 0.30 |
| Stratum 2: 16.8 g/d Patiromer | 0.41 |
| Stratum 2: 25.2 g/d Patiromer | 0.39 |
| Stratum 2: 33.6 g/d Patiromer | 0.58 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 100 |
| Stratum 1: 16.8 g/d Patiromer | 100 |
| Stratum 1: 25.2 g/d Patiromer | 98.4 |
| Stratum 2: 16.8 g/d Patiromer | 91.7 |
| Stratum 2: 25.2 g/d Patiromer | 95.8 |
| Stratum 2: 33.6 g/d Patiromer | 95.5 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 95.2 |
| Stratum 1: 16.8 g/d Patiromer | 90.8 |
| Stratum 1: 25.2 g/d Patiromer | 81.3 |
| Stratum 2: 16.8 g/d Patiromer | 79.2 |
| Stratum 2: 25.2 g/d Patiromer | 91.7 |
| Stratum 2: 33.6 g/d Patiromer | 77.3 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 86.3 |
| Stratum 1: 16.8 g/d Patiromer | 81.6 |
| Stratum 1: 25.2 g/d Patiromer | 88.9 |
| Stratum 2: 16.8 g/d Patiromer | 86.7 |
| Stratum 2: 25.2 g/d Patiromer | 89.5 |
| Stratum 2: 33.6 g/d Patiromer | 93.3 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | Days (Median) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 4 |
| Stratum 1: 16.8 g/d Patiromer | 4 |
| Stratum 1: 25.2 g/d Patiromer | 4 |
| Stratum 2: 16.8 g/d Patiromer | 8 |
| Stratum 2: 25.2 g/d Patiromer | 7.5 |
| Stratum 2: 33.6 g/d Patiromer | 8 |
Time to the first event of reduction in estimated GFR of 30ml/min/1.73m*m in individuals w/a baseline estimated GFR >= 60 ml/min/1.73m*m, reduction in estimated GFR >50% in individuals w/ baseline estimated GFR <60ml/min/1.73m*m; ESRD or death. (NCT00555217)
Timeframe: From enrollemnt to time of first primary event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 132 |
| Monotherapy ARB | 152 |
Time to the first event of reduction in estimated GFR of >50% (for individuals with baseline GFR <60) or reduction in GFR of >30 (for individuals with baseline GFR >= GFR 60) or ESRD. (NCT00555217)
Timeframe: From enrollment to time of first event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 77 |
| Monotherapy ARB | 101 |
8 trials available for losartan and Hyperkalemia
| Article | Year |
|---|---|
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Hum | 2022 |
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Diabe | 2018 |
Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study.
Topics: Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Drug Delivery Systems; Female; Follow- | 2014 |
Aliskiren and losartan trial in non-diabetic chronic kidney disease.
Topics: Amides; Blood Pressure; Comorbidity; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationsh | 2014 |
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus | 2009 |
Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan).
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cross-Over | 2004 |
Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2005 |
10 other studies available for losartan and Hyperkalemia
| Article | Year |
|---|---|
High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
Topics: Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hyperkalemia; Hypokalemia; Losartan | 2023 |
Reduced sarcolemmal expression and function of the NBCe1 isoform of the Na⁺-HCO₃⁻ cotransporter in hypertrophied cardiomyocytes of spontaneously hypertensive rats: role of the renin-angiotensin system.
Topics: Ammonium Compounds; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2014 |
Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients.
Topics: Acidosis; Adolescent; Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2014 |
Syncope caused by iatrogenic hyperkalemia.
Topics: Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Bradycardia; Cardiac Pacing, Artificial; | 2009 |
Spurious hyperkalaemia: an insight.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Chemical Analysis; False Positive Reactions; Fe | 2011 |
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study.
Topics: Anemia; Antihypertensive Agents; Cough; Creatinine; Female; Follow-Up Studies; Humans; Hyperkalemia; | 2003 |
[A case of intraoperative hyperkalemia induced with administration of an angiotensin II receptor antagonist (AIIA) and intake of dried persimmons].
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diospyros; Heart | 2004 |
[Severe hyperkalemia associated to the use of losartan and spironolactone: case report].
Topics: Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Female; Humans; | 2005 |
Combined use of enalapril and losartan to reduce proteinuria: a question of safety.
Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Child; Child | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |